Holen Sie sich die Stockscreener-App
20.88
4.09%
-0.89
Handel nachbörslich:
20.92
0.04
+0.19%
Schlusskurs vom Vortag:
$21.77
Offen:
$21.96
24-Stunden-Volumen:
497.10K
Relative Volume:
0.95
Marktkapitalisierung:
$928.17M
Einnahmen:
$10.32M
Nettoeinkommen (Verlust:
$-89.93M
KGV:
-8.6769
EPS:
-2.4064
Netto-Cashflow:
$-88.63M
1W Leistung:
-6.45%
1M Leistung:
-12.12%
6M Leistung:
+6.53%
1J Leistung:
+351.95%
1-Tages-Spanne:
$20.75
$22.95
1-Wochen-Bereich:
$20.75
$22.95
52-Wochen-Spanne:
$4.11
$25.95
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
20.88 | 967.74M | 10.32M | -89.93M | -88.63M | -2.4064 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-27 | Eingeleitet | Roth Capital | Buy |
| 2026-05-13 | Eingeleitet | BTIG Research | Buy |
| 2026-03-27 | Eingeleitet | Needham | Buy |
| 2026-02-25 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-18 | Hochstufung | Jefferies | Hold → Buy |
| 2026-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BIOAGE Labs Inc (BIOA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioAge Labs, Inc. $BIOA Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Has $30.57 Million Stock Position in BioAge Labs, Inc. $BIOA - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BIOAGE Labs Inc (BIOA) Income Statement - TradingKey
TradingKey - TradingKey
BIOAGE Labs Inc (BIOA) Balance Sheet - TradingKey
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BIOAGE Labs Inc (BIOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BIOA|BIOAGE Labs Inc|Price:21.770|Chg%:-0.130 - TradingKey
BioAge Labs, Inc. Revenue Breakdown – NASDAQ:BIOA - TradingView
BIOAGE Labs Inc (BIOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
Price to earnings forward of BioAge Labs, Inc. – FWB:Y7G - TradingView
BIOA Q1 2026 Earnings: EPS Beat Surprise but Stock Drops on Pre-Revenue StatusInterim Report - dars.gov.et
HitGen partner BioAge begins phase 2 trial of BGE-102 By Investing.com - Investing.com Nigeria
HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102 - TradingView
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction - The Manila Times
HitGen partner BioAge begins phase 2 trial of BGE-102 - Investing.com
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction – Company AnnouncementFT.com - Financial Times
Price to book forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BioAge Labs, Inc. begins Phase 2 trial for obesity and cardiovascular risk treatment - Traders Union
How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure - simplywall.st
BioAge Labs: Buy Rating Reiterated on NLRP3 Pathway Validation Potential; $50 Price Target Maintained - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge advances inflammaging drug into Phase 2 - Longevity.Technology
Price to sales forward of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
Enterprise value to EBITDA forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
BIOA Final Opportunity to Lead BioAge Labs, Inc. Securities Frau - GuruFocus
Price to earnings forward of BioAge Labs, Inc. – DUS:Y7G - TradingView
Bioage Labs stock hits 52-week high at 25.8 USD - Investing.com
Bioage Labs stock hits 52-week high at 25.8 USD By Investing.com - Investing.com Nigeria
Why BioAge Labs (BIOA) Is Up 6.3% After Starting QUELL-CV Phase 2 Trial For BGE-102 - Sahm
BioAge Labs principal accounting officer sells $1.57m in stock By Investing.com - Investing.com India
Form 4 Bioage Labs Inc For: 1 July By Investing.com - Investing.com Nigeria
BioAge Labs, Inc. Securities Fraud Class Action Lawsuit Pending: - GuruFocus
Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing - Moomoo
BioAge Labs principal accounting officer sells $1.57m in stock - Investing.com
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
BioAge Labs Inc. (BIOA) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplineFinal Results - dars.gov.et
BioAge Labs Hits Day High with 9.98% Surge, Outperforming Market - MarketsMojo
BioAge Labs (BIOA) Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Biotech Development StageMid-Term Outlook - dars.gov.et
BIOA (NASDAQ: BIOA) Form 144 filed for 42,350-share proposed sale - Stock Titan
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation? - Yahoo Finance
Form 144 BioAge Labs For: 29 June By Investing.com - Investing.com Nigeria
BIOA (BIOA) Form 144 lists proposed sales of 2,632 and 39,718 shares - Stock Titan
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2000 Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 3000E Growth Benchmark - marketscreener.com
BioAge Labs, Inc.(NasdaqGS: BIOA) added to Russell 2500 Growth Benchmark - marketscreener.com
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):